section name header

Introduction

The antibacterial group of drugs has proliferated immensely since the first clinical use of sulfonamide in 1936 and the mass production of penicillin in 1941. In general, harmful effects have resulted from allergic reactions or inadvertent intravenous overdose. Serious toxicity from a single acute ingestion is rare. Table II-4 lists common and newer antibacterial agents that have been associated with significant toxic effects.

TABLE II-4. ANTIBACTERIAL DRUGS
DrugToxicity

Aminoglycosides

Amikacin

Gentamicin

Kanamycin

Neomycin

Streptomycin

Tobramycin

Toxic to vestibular and cochlear cells; nephrotoxicity causing proximal tubular damage and acute tubular necrosis; competitive neuromuscular blockade if given rapidly IV with other neuromuscular-blocking drugs. Threshold for toxic effects varies with the drug, dosage schedule, treatment duration, and sampling time.
Antimycobacterials
BedaquilineQT prolongation, hepatotoxicity
EthambutolOptic neuritis, red-green color blindness, peripheral neuropathy. Risk of ocular adverse effects increases with dose: 1% at 15 mg/kg/d, 5% at 25 mg/kg/d, 18% at 35 mg/kg/d.
EthionamideSevere nausea/vomiting, hepatitis, hypothyroidism, hypoglycemia, photosensitivity, neurotoxic effects
Isoniazid (INH)Convulsions, metabolic acidosis, hypotension, acute hepatic failure; hepatotoxicity, peripheral neuropathy, and psychosis with chronic use
PretomanidPeripheral neuropathy, hepatotoxicity (with linezolid and bedaquiline)
PyrazinamideHepatotoxicity, hyperuricemia
Rifampin, rifabutin, rifapentineAll patients will develop harmless red discoloration of urine, sweat, and tears. With acute exposure, abdominal pain, vomiting and diarrhea (may be red), facial edema, pruritus. Severe toxicity includes acute hepatic failure, seizures, cardiac arrest. Antibiotics of rifamycin class are inducers of hepatic cytochrome P450 enzymes, especially CYP3A4.
BacitracinMinimal enteric systemic absorption; if administered parenterally or absorbed via breaks in skin, ototoxicity and nephrotoxicity

Carbapenems

Doripenem

Ertapenem

Imipenem/cilastatin

Meropenem

Hypersensitivity reactions; seizures associated with renal dysfunction and high doses. Highest seizure risk with imipenem.
CephalosporinsHypersensitivity reactions; convulsions reported in patients with renal insufficiency and excessive doses

Cefazolin

Cephalothin

Coagulopathy associated with cefazolin
CefaclorNeutropenia

Cefoperazone

Cefamandole

Cefotetan

Moxalactam

Cefmetazole

One case of symptomatic hepatitis. All these antibiotics have the N-methylthiotetrazole side chain, which may inhibit aldehyde dehydrogenase to cause a disulfiram-like interaction with ethanol and coagulopathy (inhibition of vitamin K production).
CeftriaxonePseudolithiasis (“gallbladder sludge”). IV dose should be given over at least 30 min
CefepimeEncephalopathy, myoclonic and nonconvulsive status epilepticus associated with high doses, renal dysfunction.
CefiderocolTransaminase elevation, hypokalemia, nausea, vomiting, diarrhea
ChloramphenicolLeukopenia, reticulocytopenia, circulatory collapse (“gray baby” syndrome)
Clindamycin, lincomycinHypotension and cardiopulmonary arrest after rapid intravenous administration
DaptomycinMay cause muscle pain, weakness, or asymptomatic elevation of the CK level. Rare cases of rhabdomyolysis, dosage-related.
FidaxomicinMinimal systemic absorption; nausea/vomiting/abdominal pain possible
Folate antagonistsBone marrow suppression
PyrimethamineSeizures, hypersensitivity reactions, folic acid deficiency
TrimethoprimMethemoglobinemia, hyperkalemia
FosfomycinLow serum concentrations with oral administration; nausea, vomiting. Ototoxicity and taste disturbances in overdoses
Glycopeptides
DalbavancinHighly protein bound; administered once weekly. Possible hepatotoxicity, bleeding risk; accidental double dose (3,000 mg) caused mild diarrhea.
OritavancinHighly protein bound; administered once weekly. P450 drug interactions. Interferes with coagulation lab tests (aPTT, INR).
TelavancinNephrotoxic; may cause QTc prolongation, foamy urine, “red man” syndrome; interferes with coagulation tests.
VancomycinNephrotoxic at high doses. Hypotension, skin rash/flushing (“red man” syndrome) associated with rapid IV administration. Possible ototoxicity.
GramicidinTopical/ophthalmic agent. Hemolysis if systemically absorbed.
LefamulinQT prolongation, transaminase elevation; fetal harm in animals.
Linezolid, tedizolidThrombocytopenia, anemia; lactic acidosis (rare); peripheral neuropathy and optic neuritis with prolonged use. Linezolid is an inhibitor of monoamine oxidase; serotonin syndrome reported when combined with antidepressants.
MacrolidesCan prolong the QT interval and lead to torsade de pointes (atypical ventricular tachycardia). Inhibitors of CYP enzymes.
AzithromycinLeast likely of the macrolides to induce torsade in animal studies and least potent P450 inhibitor.
ClarithromycinFatal hepatotoxicity reported (rare)
DirithromycinHepatotoxicity
ErythromycinAbdominal pain; idiosyncratic hepatotoxicity with estolate salt. Administration of more than 4 g/d may cause tinnitus, ototoxicity.
Tilmicosin (veterinary drug)Cardiotoxic: tachycardia, decreased contractility, cardiac arrest
NitrofurantoinNausea/vomiting with acute overdose; hemolysis in G6PD-deficient patients is possible. Pulmonary hypersensitivity reactions with long-term use.
NitroimidazolesSeizures with acute overdose; peripheral neuropathy with chronic use; disulfiram-like reactions with ethanol
Metronidazole
Tinidazole
PenicillinsHypersensitivity reactions; seizures with single high dose or chronic excessive doses in patients with renal dysfunction
Ampicillin, amoxicillinHigh doses can cause acute kidney injury by crystal deposition; amoxicillin-clavulanate can cause liver injury.
MethicillinInterstitial nephritis, leukopenia
NafcillinNeutropenia
Penicillin GAdministration of long-acting IM salt formulations (benzathine, procaine) via IV route associated with cardiovascular collapse and death.

Penicillins, anti-pseudomonal

Carbenicillin

Mezlocillin

Piperacillin/ tazobactam

Ticarcillin

May interfere with platelet function; hypokalemia due to renal loss. Most formulations contain 2-5 mEq of sodium per gram of drug. Risk for toxicity higher in patients with renal insufficiency.

Polymyxins

Polymyxin B

Polymyxin E (colistin)

Nephrotoxicity and noncompetitive neuromuscular blockade
QuinolonesTendonitis and tendon rupture (higher risk with increased age, corticosteroid use, renal dysfunction). Potentially irreversible peripheral neuropathy. Some agents can prolong the QT interval. Headache, dizzinesss, seizures. Acute liver injury. Dysglycemia in susceptible populations.
CiprofloxacinCrystalluria associated with doses above daily maximum and with alkaline urine. Inhibits CYP1A2 - interactions with theophylline and caffeine.
GatifloxacinCase reports of induced cholestatic hepatitis and hallucinations. Hypoglycemia or hyperglycemia. Oral and parenteral products withdrawn from US market.
GemifloxacinEncephalopathy.
LevofloxacinHepatotoxicity, vision impairment, pseudotumor cerebri, autoimmune hemolytic anemia; interactions with herbal and natural supplements may cause cardiotoxicity.
LomefloxacinPhototoxicity, seizures.
MoxifloxacinHighest QT prolongation of quinolones available in the United States.
Nalidixic acidMetabolic acidosis; intracranial hypertension
NorfloxacinCrystalluria associated with doses above daily maximum and with alkaline urine
OfloxacinNeuropsychiatric symptoms: agitation, confusion, hallucination, psychosis.
SparfloxacinAssociated with prolonged QT interval and torsade de pointes. Photosensitivity (use at least SPF 15 in sun-exposed areas).
Sulfonamides and SulfonesHypersensitivity reactions, including severe rash; frequently co-administered with folate antagonists
DapsoneMethemoglobinemia (see), sulfhemoglobinemia, hemolysis; metabolic acidosis; hallucinations, confusion; hepatotoxicity
SulfamethoxazoleAcute renal failure caused by crystal deposition
TetracyclinesUse of tetracyclines may discolor/damage developing teeth, avoid in pregnancy and children <8 y. Risk of fetal harm in pregnancy.
DemeclocyclineNephrogenic diabetes insipidus
DoxycyclineRare esophageal ulceration
MinocyclineVestibular symptoms
TetracyclineBenign intracranial hypertension. Degradation products (eg, expired prescriptions) are nephrotoxic, may cause Fanconi-like syndrome. Some products contain sulfites. Doses >4 g/d can cause acute fatty liver in pregnant women.
TigecyclineNausea and vomiting common; coagulopathy (rare).

Mechanism of Toxicity

The precise mechanisms underlying toxic effects vary with the agent and are not well understood.

  1. In some cases, toxicity is caused by an extension of pharmacologic effects, whereas in other cases, allergic or idiosyncratic reactions are responsible (especially penicillins, cephalosporins, and sulfonamides).
  2. Some IV preparations may contain preservatives such as benzyl alcohol or large amounts of potassium or sodium.
  3. Drug interactions may increase toxic effects by inhibiting metabolism of the antibacterial; macrolides are frequently implicated in drug-drug interactions.
  4. Prolonged QT interval and torsade de pointes (atypical ventricular tachycardia) have emerged as serious effects of macrolides or quinolones when they are used alone or interact with other medications.

Toxic Dose

The toxic dose is highly variable, depending on the agent. Life-threatening allergic reactions may occur even after subtherapeutic doses in hypersensitive individuals.

Clinical Presentation

After acute oral overdose, most agents cause only nausea, vomiting, and diarrhea. Specific features of toxicity are described in Table II-4.

Diagnosis

Is usually based on the history of exposure.

  1. Specific levels. Serum levels for antibacterials are typically only rapidly available for aminoglycosides and vancomycin; there is a relatively predictable concentration-toxicity relationship for these agents.
  2. Other useful laboratory studies include CBC, electrolytes, glucose, BUN, creatinine, liver function tests, urinalysis, creatine kinase, ECG (including QT interval), and methemoglobin level (for patients with dapsone overdose) via CO-oximetry.

Treatment

  1. Emergency and supportive measures
    1. Maintain an open airway and assist ventilation if necessary.
    2. Treat coma, seizures, hypotension, anaphylaxis, and hemolysis (see “Rhabdomyolysis,”) if they occur.
    3. Replace fluid losses resulting from gastroenteritis with IV crystalloids.
    4. Maintain steady urine flow with fluids to alleviate crystalluria from overdoses of sulfonamides, ampicillin, or amoxicillin.
  2. Specific drugs and antidotes
    1. Trimethoprim or pyrimethamine poisoning: Administer leucovorin (folinic acid). Folic acid is not effective.
    2. Dapsone overdose (see also): Administer methylene blue for symptomatic methemoglobinemia.
    3. Treat isoniazid (INH) overdose (see also) with pyridoxine.
  3. Decontamination. Administer activated charcoal orally if conditions are appropriate (see Table I-37). Gastric lavage is not necessary after small-to-moderate ingestions if activated charcoal can be given promptly.
  4. Enhanced elimination. Most antibacterials are excreted unchanged in the urine, therefore maintenance of adequate urine flow is important. Extracorporeal removal is not usually indicated, except in patients with renal dysfunction and a high level of a toxic agent.
    1. Dapsone undergoes enterohepatic recirculation and is eliminated more rapidly with repeat-dose activated charcoal.
    2. Hemodialysis may remove isoniazid, but it is rarely indicated due to the short half-life of isoniazid and generally adequate response to treatment with benzodiazepines and pyridoxine.

Introduction

Mechanism of Toxicity

Toxic Dose

Clinical Presentation

Diagnosis

Treatment